The treatment of chronic recurrent pancreatitis with depot secretin--a preliminary report.
Increased viscosity and raised lactoferrin, trypsin and protein concentrations in selectively aspirated pancreatic secretion, prompted us to try depot secretin therapy in patients with advanced chronic recurrent pancreatitis without pancreatic duct obstruction or pancreatic pseudocysts. The idea behind this approach was that it might "wash out" the sticky, protease-rich secretion. In a randomized double-blind trial we administered depot secretin at doses of 800 CU by subcutaneous injection twice daily for 7 days. Pancreatic secretion from the treatment group had significantly lower viscosities and lactoferrin and trypsin concentrations than in the placebo group. There was also significant pain relief. Depot secretin therapy appears to offer an alternative approach to the management of advanced chronic recurrent pancreatitis without pancreatic duct obstruction or pseudocysts.
D000681:Amylases / Q000097:blood; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007781:Lactoferrin / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010189:Pancreatic Juice / Q000378:metabolism; D010195:Pancreatitis / Q000188:drug therapy*; D011897:Random Allocation; D012008:Recurrence; D012633:Secretin / Q000627:therapeutic use*; D014357:Trypsin / Q000378:metabolism; D014783:Viscosity
D003692:Delayed-Action Preparations; D012633:Secretin; D000681:Amylases; D007781:Lactoferrin; D014357:Trypsin